Stockscreener 앱 받기
0.9951
2.44%
-0.0249
시간 외 거래:
1.00
0.0049
+0.49%
전일 마감가:
$1.02
열려 있는:
$0.93
하루 거래량:
5,302
Relative Volume:
0.25
시가총액:
$18.32M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+5.30%
1개월 성능:
-7.86%
6개월 성능:
-73.11%
1년 성능:
-82.53%
1일 변동 폭
$0.93
$1.0176
1주일 범위
$0.89
$1.12
52주 변동 폭
$0.87
$8.60
Lakeshore Biopharma Co Ltd Stock (LSB) Company Profile
LSB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LSB
Lakeshore Biopharma Co Ltd
|
0.9951 | 18.32M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lakeshore Biopharma Co Ltd 주식(LSB)의 최신 뉴스
Comparing Fulcrum Therapeutics (NASDAQ:FULC) and Lakeshore Biopharma (NASDAQ:LSB) - Defense World
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - marketscreener.com
Lakeshore Biopharma Dave Chenn Resigned As Chairman - marketscreener.com
LakeShore Biopharma Announces Leadership Change with New Chairman Appointment - TipRanks
LakeShore Biopharma Enters Financing Lease Agreement for RMB110 Million - TipRanks
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell) - The Manila Times
Revolutionary Needle-Free Technology Transforms Rabies Vaccine Delivery: China's First Smart Packaging Solution - Stock Titan
TuHURA Biosciences (NASDAQ:HURA) vs. Lakeshore Biopharma (NASDAQ:LSB) Head-To-Head Contrast - Defense World
LakeShore Biopharma Announces Court Dismissal Of Former Chairman's Injunction Applications - MarketScreener
LakeShore Biopharma Adopts Amended Share Incentive Plan - TipRanks
YS Biopharma Shares Surge 18% Pre-Bell on Estimated Preliminary Revenue for Fiscal Year 2023 - Marketscreener.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Revenues Working Against LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Share Price Following 27% Dive - Simply Wall St
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance - Finansavisen
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China - GlobeNewswire
LakeShore Biopharma Initiates Biologics License Application - GlobeNewswire
LakeShore Biopharma Co., Ltd Provides Financial Guidance for the Half Year of Fiscal Year of 2025 and Full Year of Fiscal Year 2025 Ending on March 31, 2025 - MarketScreener
Investors Don't See Light At End Of LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Tunnel And Push Stock Down 66% - Simply Wall St
LakeShore Biopharma regains Nasdaq compliance - Investing.com
LakeShore Biopharma’s YSJA Rabies Vaccine Heads to Phase III Trial - Contract Pharma
YS Biopharma (YSB) Stock Price, News & Analysis - MarketBeat
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance - 팜뉴스
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation - PR Newswire
LakeShore changes CEO with new executive appointments - The Pharma Letter
LakeShore Biopharma Announces Leadership Transitions - PR Newswire
YS Biopharma COVID-19 Vaccine Candidate Against Omicron Variant Meets Primary, Secondary Goals - Marketscreener.com
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 - PR Newswire
LakeShore Biopharma Insider Ups Holding By 3,083% During Year - simplywall.st
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition - PR Newswire
LakeShore Biopharma Co., Ltd (NASDAQ:LSB): When Will It Breakeven? - Yahoo Finance
LSB Stock Price and Chart — NASDAQ:LSB - TradingView
YS Biopharma Co., Ltd. will Change its Ticker to LSB from YS - Marketscreener.com
YS Biopharma Announces Name Change to LakeShore Biopharma - PR Newswire
YS Biopharma Announces Results of Extraordinary General Meeting - PR Newswire
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer - PR Newswire
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - PR Newswire
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine - PR Newswire
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries - PR Newswire
YS Biopharma Announces Appointment of New Directors - PR Newswire
YS Biopharma Announces US$40 Million Private Placement Financing - PR Newswire
YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting - Marketscreener.com
Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target - PR Newswire
YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023 - Marketscreener.com
YSYS Biopharma Co., Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Lakeshore Biopharma Co Ltd (LSB) 재무 분석
Lakeshore Biopharma Co Ltd (LSB)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.68%
0.50%
자본화:
|
볼륨(24시간):